{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:59:31Z","timestamp":1779379171118,"version":"3.53.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background\/Aims:<\/jats:bold> Rheumatoid arthritis (RA) is associated with the emergence of cardiovascular disease, while chronic inflammation is considered a common denominator for their parallel progression. The Proprotein convertase subtilisin\/kexin type 9 (PCSK9)\/LDL-Receptor (LDLR) system is of high importance during atherogenesis, via regulating the clearance of LDL from the circulation; nevertheless the role of this molecular mechanism during RA-related atheromatosis is not known.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Herein, high-resolution ultrasound measurements for arterial hypertrophy, atheromatosis and arterial stiffness as well as comprehensive biochemical profiling were performed in 85 RA patients. The circulating levels of PCSK9 and LDLR were measured and their potential associations as well as of the PCSK9\/LDLR ratio with patients' characteristics and the degree of atherosclerosis were investigated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Increased LDLR levels and decreased PCSK9\/LDLR ratio were found in RA patients with at least 2 atheromatic plaques as compared to the ones without any plaques. In addition the levels of both PCSK9 and LDLR were positively correlated with the presence of atheromatic plaques as an age- and gender- adjusted multivariate analysis revealed.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our data imply that the PCSK9\/LDLR system plays a significant role during RA-related atherosclerosis and may therefore be used as a screening tool for disease progression in the future.<\/jats:p>","DOI":"10.3389\/fcvm.2021.738764","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T15:18:21Z","timestamp":1633879101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["PCSK9\/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis"],"prefix":"10.3389","volume":"8","author":[{"given":"Aikaterini","family":"Arida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigli-Ioanna","family":"Legaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evrydiki","family":"Kravvariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Protogerou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Chatzigeorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10067-015-2914-1","article-title":"Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors","volume":"34","author":"Arida","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1161\/ATVBAHA.109.190108","article-title":"Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study","volume":"29","author":"Stamatelopoulos","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","article-title":"Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis","volume":"78","author":"Boyer","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/ijms19071890","article-title":"Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases","volume":"19","author":"Arida","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1161\/01.CIR.100.21.2124","article-title":"A tale of two diseases: atherosclerosis and rheumatoid arthritis","volume":"100","author":"Pasceri","year":"1999","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","article-title":"A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","volume":"10","author":"Wadhera","year":"2016","journal-title":"J Clin Lipidol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.taap.2019.03.018","article-title":"Emerging role of proprotein convertase subtilisin\/kexin type-9 (PCSK-9) in inflammation and diseases","volume":"370","author":"Brown","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2016.04.103","article-title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study","volume":"215","author":"Xie","year":"2016","journal-title":"Int J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.hjc.2018.05.003","article-title":"Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias","volume":"60","author":"Vlachopoulos","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bbrc.2017.02.085","article-title":"PCSK9 regulates the chemokine receptor CCR2 on monocytes","volume":"485","author":"Grune","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating HS-CRP levels: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open."},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int J Mol Med"},{"key":"B25","first-page":"1013","article-title":"Proprotein convertase subtilisin\/kexin type 9 in rheumatoid arthritis","volume":"34","author":"Ferraz-Amaro","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1136\/annrheumdis-2013-204933","article-title":"Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox","volume":"73","author":"Gonzalez-Gay","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B28","first-page":"655","article-title":"[The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis]","volume-title":"Zhonghua Nei Ke Za Zhi","author":"Du","year":"2017"},{"key":"B29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1046\/j.1432-1033.2003.03953.x","article-title":"Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters","volume":"271","author":"Begg","year":"2004","journal-title":"Eur J Biochem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jcla.21727","article-title":"Association between serum soluble low-density lipoprotein receptor levels and metabolic factors in healthy Japanese individuals","volume":"29","author":"Shimohiro","year":"2015","journal-title":"J Clin Lab Anal"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1210\/jc.2018-00777","article-title":"Associations between soluble LDLR and lipoproteins in a white cohort and the effect of PCSK9 loss-of-function","volume":"103","author":"Mayne","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12944-020-1199-9","article-title":"The enigma of soluble LDLR: could inflammation be the key?","volume":"19","author":"Mbikay","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/a-0833-4627","article-title":"Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients","volume":"51","author":"Ferraz-Amaro","year":"2019","journal-title":"Horm Metab Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","article-title":"Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms","volume":"23","author":"Frostegard","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/jcm9040910","article-title":"Methotrexate decreases the level of PCSK9-A novel indicator of the risk of proatherogenic lipid profile in psoriasis. The preliminary data","volume":"9","author":"Krahel","year":"2020","journal-title":"J Clin Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.738764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T15:18:26Z","timestamp":1633879106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.738764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":35,"alternative-id":["10.3389\/fcvm.2021.738764"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.738764","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"738764"}}